Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology
Company®, today announced that it will be showcasing its latest
Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein
biomarkers) spatial phenotyping data at the Society for
Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in
San Diego, California, November 1-5, 2023.
At booth #719, Akoya Biosciences will highlight its new
PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platforms, which
offer significant advancements in speed and scale for spatial
biology research.
- PhenoCycler-Fusion
2.0: Features multi-slide automation, enabling researchers to
generate ultrahigh-plex spatial phenotyping data for larger and
more complex samples at unprecedented speed.
- PhenoImager HT 2.0:
Features onboard spectral unmixing, which accelerates biomarker
development and validation workflows.
“We continue to evolve our spatial biology platforms to enable
even greater speed and scale, which is essential for our customers
as they discover and validate new biomarkers,” said Brian
McKelligon, CEO of Akoya Biosciences. “We’re excited to be at SITC
where we will highlight these innovations and share an extensive
array of new spatial phenotyping data. Many members of our global
network of CRO service providers will also be at SITC. These
organizations are a critical resource for biopharmaceutical
companies as the industry continues to integrate spatial biology
into their discovery and translational workflows.”
Ultrahigh-plex Spatial Phenotyping Reveals Markers
Associated with Response to Immunotherapy
Among the posters being presented at SITC is one describing the
spatial tumor microenvironment landscapes of cutaneous squamous
cell carcinoma (cSCC) tissues from patients over the course of
immunotherapy treatment. An ultrahigh-plex antibody panel
encompassing cell lineages, activation states, immune checkpoints,
structural and metabolic markers was deployed on the
PhenoCycler-Fusion platform for analysis of the tissue
microenvironment. Cellular phenotypes, spatial neighborhoods and
functional states driving tumor pathogenesis and response to
immunotherapy were identified. The poster will be presented by
Arutha Kulasinghe, Ph.D., leader of the Clinical-oMx Group at the
Frazer Institute of the University of Queensland, Australia, and
founding scientific director of the Queensland Spatial Biology
Centre.
Dr. Kulasinghe, his colleagues, and Akoya collaborators recently
published a peer-reviewed article describing another ultrahigh-plex
spatial biology study that revealed a high degree of intra-tumoral
heterogeneity and distinct immune microenvironments in a tumor
tissue section from a head and neck squamous cell carcinoma (HNSCC)
patient with a partial response to treatment with an immune
checkpoint inhibitor.
These studies reinforce the value of single-cell ultrahigh-plex
spatial phenotyping as a powerful tool for defining spatial tissue
signatures associated with therapy response and resistance.
Expanding Global Network of Contract Research
Organizations (CROs) Providing Spatial Phenotyping
Solutions
Fourteen of Akoya’s eighteen qualified CRO service providers
will also be exhibiting at SITC. Akoya’s CRO network continues to
grow rapidly, reflecting the demand for spatial phenotyping
solutions across the biopharmaceutical industry. Offering biomarker
testing services, these CROs enable drug developers and academic
research institutions to accelerate the discovery and development
of new immuno-therapies.
“We have seen great success leveraging Akoya’s ultrahigh-plex
spatial biology technology to deliver better insights into the
tumor microenvironment for our biopharma clients,” said Christiaan
Neelemen, President, Research & Clinical Services, Discovery
Life Sciences, a member of Akoya’s CRO network providing end-to-end
spatial immunophenotyping services to help define mechanisms of
action, disease indications, and patient stratification. “With
Akoya’s reliable multiplex technology, we can perform faster and
higher quality analysis on a single tissue slide, helping us better
understand complex disease mechanisms so our clients can develop
more effective treatments.”
“The demand for spatial phenotyping services and analysis
continues to grow at an unprecedented pace,” said Sunil Bodapati,
Co-Founder and Chief Executive Officer of Enable Medicine, also a
member of Akoya’s CRO network. “Akoya’s spatial biology platforms
offer a combination of speed, throughput, and workflow efficiency.
Our analysis platform, applied to high-plex datasets, allows us to
rapidly deliver the spatial insights our clients need to advance
their discovery and translational research and set the stage for
the long-term success of their initiatives.”
Details of the SITC posters to be presented by Akoya and
collaborators are as follows:
Title: The Mutational Landscape Defines the
Proteome and Spatial Organization of Tumor, Stroma, andImmune Cells
in Ovarian CancerSession Date and Time: Friday,
Nov. 3 from 9 a.m.–7 p.m. Poster Number: 75
Title: Ultrahigh-plex Spatial Phenotyping of
the Glioma Tumor Landscape in IDH-1wt and IDH-1R132H Patient
TissuesSession Date and Time: Friday, Nov. 3 from
9 a.m.–7 p.m.Poster Number: 97
Title: Identifying a Role for Macrophages in
Predicting Immunotherapy Responses of Non-Small Cell Lung Cancer
(NSCLC)Session Date and Time: Friday, Nov. 3 from
9 a.m.–7 p.m.Poster Number: 105
Title: High Dimensional to High-throughput
Spatial Phenotyping: An Integrated Pathway from Discovery to
Translational and Clinical StudiesSession Date and
Time: Friday, Nov. 3 from 9 a.m.–7 p.m.Poster
Number: 117
Title: Temporo-Spatial Monitoring of the Tumor
Microenvironment in Cutaneous Squamous CellCarcinomaSession
Date and Time: Saturday, Nov. 4 from 9 a.m.–8:30
p.m.Poster Number: 90
Title: Location, Location, Location: Spatial
Analysis of Ultrahigh-Plex Immunofluorescence Panel in Headand Neck
CancerSession Date and Time: Saturday, Nov. 4 from
9 a.m.–8:30 p.m.Poster Number: 124
Title: Successful Immune-Checkpoint Therapy
Promotes Spatial Reorganization of the Lymphoid andMyeloid Cellular
PopulationsSession Date and Time: Saturday, Nov. 4
from 9 a.m.–8:30 p.m.Poster Number: 570
For more information about Akoya’s activities at SITC 2023,
please visit our website.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
expectations about the potential of our products and services and
other matters regarding our business strategies and plans and
objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciencesinvestors@akoyabio.com
Media Contact:Christine
Quern617-650-8497media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Akoya BioSciences (NASDAQ:AKYA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024